Hyperfine Inc (NASDAQ:HYPR) Reports Mixed Q3 2025 Results, Provides Q4 Outlook

Hyperfine Inc (NASDAQ:HYPR) reported its financial results for the third quarter of 2025, delivering a mixed performance against analyst expectations. The company, known for its portable Swoop® brain imaging system, showed sequential revenue growth while continuing to post a net loss, a common stage for commercial-stage medical technology firms.

Earnings and Revenue Versus Estimates

The company’s top-line performance slightly missed the mark set by Wall Street, while its bottom-line loss was marginally wider than anticipated.

• Q3 2025 Revenue: $3.4 million, compared to analyst estimates of $3.53 million.
• Q3 2025 EPS (Non-GAAP): A loss of $0.14 per share, compared to an estimated loss of $0.11 per share.

Despite the slight miss on revenue, the figure represents a 27% increase compared to the second quarter of 2025, indicating positive sequential momentum in the company's commercial activities. The net loss for the quarter was $11.0 million, which included a non-cash charge of $2.3 million related to the change in fair value of warrant liabilities.

Market Reaction and Price Action

Following the earnings release, the market reacted negatively in after-hours trading. The stock was down approximately 3.8%, suggesting investor disappointment with the earnings and revenue miss against estimates. This immediate reaction highlights the market's focus on the company's ability to meet or exceed quarterly financial targets during its growth phase.

Management's Forward Outlook

A potentially significant factor for investors is the company's provided guidance for the fourth quarter, which appears ambitious when held against existing analyst projections.

• Hyperfine's Q4 2025 Revenue Guidance: $5 to $6 million.
• Analyst Estimate for Q4 2025 Revenue: $6.1 million.

At the midpoint of its guidance ($5.5 million), Hyperfine's forecast falls short of the current analyst consensus. This may have contributed to the negative after-hours price action, as it suggests the company's near-term growth trajectory may be slower than the market had hoped. For the full year 2025, management now expects revenue of $13 to $14 million.

Business Highlights and Operational Progress

Beyond the quarterly numbers, the earnings report emphasized several operational milestones that management believes will drive future growth. The commercial launch of the next-generation Swoop® system, powered by Optive AI™ software, was a central theme. The company reported successfully placing these new systems across various sites of care, including critical care units and neurology offices, and has converted its entire U.S. hospital pipeline to the new model.

Furthermore, Hyperfine has initiated a full-scale commercial launch in the neurology office setting, a new market opportunity, and has obtained CE Mark and UKCA Mark approvals for its Optive AI™ software, facilitating its rollout in international markets. The company also strengthened its balance sheet by raising $20.1 million in gross proceeds through a public offering in October 2025.

Conclusion

Hyperfine's third-quarter results paint a picture of a company in transition, demonstrating solid sequential growth but falling just short of quarterly expectations. The market's negative reaction appears to be a response to both the earnings miss and a fourth-quarter revenue outlook that trails analyst estimates. However, the company continues to execute on its commercial strategy, launching new products and expanding into new care settings, which it expects to diversify and accelerate its growth.

For a detailed look at Hyperfine's historical earnings and future analyst estimates, you can review the data here.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The author has no position in HYPR. Investors should conduct their own research and consider their individual financial circumstances before making any investment decisions.